MedicalResearch.com Interview with:
[caption id="attachment_16840" align="alignleft" width="124"]
Dr. Csaba P. Kovesdy[/caption]
Csaba P Kovesdy MD FASN
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clinical Trials Program
Division of Nephrology, University of Tennessee Health Science Center
Nephrology Section Chief, Memphis VA Medical Center
Memphis TN, 38163
MedicalResearch.com: What is the background for this study?
Response: Microinflammation may be a mechanism contributing to adverse outcomes in patients with chronic kidney disease (CKD). Low dose aspirin (ASA) is usually used as an antiplatelet agent for cardiovascular indications, but may also have beneficial effects on kidney function by reducing microinflammation.
